Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Fig. 3

Monitoring the quantity of flow-MRD until clinical progression across six patients with clinical progression reveals, that flow-MRD positivity precedes substantial changes in clinical monitored values for sFLCr, SPEP and IF, and subsequent clinical progression. Time from inclusion to measured flow-MRD positivity varied from 5.9–64.4 month (Mean 19.1 month). MRD positivity was detected with a mean of 12.6 month (range 9.6–26.6) before clinical progression (according to IMWG standard) was recorded. Median mPC doubling time was calculated to 1.8 month (1.4–2.3) across the six patients, fitting a log-linear model for mPC concentration (mPC/ × 106 events) versus time to clinical progression. X-axis: Timeline (months to clinical progression). Y-axis: mPC frequency. Achieved flow-MRD detection limit for the MRD+ patient group is shown as a dotted horizontal line. Abbreviations: MRD: Minimal residual disease. PID: Patient identification ID. SCR: Stringent complete response. SFLCr: Serum free light chain ratio (abnormal/normal). IF: Immunofixation (positive/negative) SPEP: Serum protein electrophoresis (positive/negative). Lin: Linear. Log: Logarithmic. nd: not determined. “0”: Flow-MRD negative

Back to article page